These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19149502)

  • 1. Recent advances in obesity pharmacotherapy.
    Mayer MA; Höcht C; Puyó A; Taira CA
    Curr Clin Pharmacol; 2009 Jan; 4(1):53-61. PubMed ID: 19149502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
    Rubio MA; Gargallo M; Isabel Millán A; Moreno B
    Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk.
    Caterson ID; Finer N
    Asia Pac J Clin Nutr; 2006; 15 Suppl():55-62. PubMed ID: 16928662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
    Halford JC
    Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacotherapy in the treatment of obesity].
    Hamann A
    MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
    Padwal RS; Majumdar SR
    Lancet; 2007 Jan; 369(9555):71-7. PubMed ID: 17208644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy for obesity.
    Neff LM; Aronne LJ
    Curr Atheroscler Rep; 2007 Dec; 9(6):454-62. PubMed ID: 18377785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug treatment of obesity].
    Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
    Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic treatment for obesity. Options for today...and tomorrow.
    Lundquist LM; Sirimaturos M; Cannon E
    Adv Nurse Pract; 2006 Aug; 14(8):31-5, 64. PubMed ID: 16972485
    [No Abstract]   [Full Text] [Related]  

  • 11. A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity.
    Gray LJ; Cooper N; Dunkley A; Warren FC; Ara R; Abrams K; Davies MJ; Khunti K; Sutton A
    Obes Rev; 2012 Jun; 13(6):483-98. PubMed ID: 22288431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
    Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
    Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy for obesity.
    Li M; Cheung BM
    Br J Clin Pharmacol; 2009 Dec; 68(6):804-10. PubMed ID: 20002075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoid system as a target for obesity treatment.
    Aronne LJ; Pagotto U; Foster GD; Davis SN
    Clin Cornerstone; 2008; 9(1):52-64; discussion 65-6. PubMed ID: 19046740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacotherapy of obesity].
    Hamann A
    Internist (Berl); 2008 Jan; 49(1):106-13. PubMed ID: 18060334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
    Leung WY; Thomas GN; Chan JC; Tomlinson B
    Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacotherapy of obesity].
    Rotthoff T; Scherbaum WA
    Med Monatsschr Pharm; 2006 Dec; 29(12):433-8; quiz 439-40. PubMed ID: 17220037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity and cardiovascular physiology: impact of some pharmacological agents.
    Chaput JP; Bérubé-Parent S; Tremblay A
    Curr Vasc Pharmacol; 2005 Apr; 3(2):185-93. PubMed ID: 15853638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
    Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS
    Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy to reduce visceral fat.
    Blackburn GL; Waltman BA
    Clin Cornerstone; 2005; 7(2-3):52-60. PubMed ID: 16473261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.